Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention

Topic: Amyloid, tau and blood-test diagnosis

The most prevalent form of dementia in the elderly is Alzheimer's disease. A significant contributing factor to the progression of the disease appears to be the progressive accumulation of amyloid-β42 (Aβ42), a small hydrophobic peptide. Unfortunately, attempts to develop therapies targeting the accumulation of Aβ42 have not been successful to treat or even slow down the disease. It is possible that this failure is an indication that targeting downstream effects rather than the accumulation of the peptide itself might be a more effective approach. The accumulation of Aβ42 seems to affect various aspects of physiological cell functions. In this review, we provide an overview of the evidence that implicates Aβ42 in synaptic dysfunction, with a focus on how it contributes to defects in synaptic vesicle dynamics and neurotransmitter release. We discuss data that provide new insights on the Aβ42 induced pathology of Alzheimer's disease and a more detailed understanding of its contribution to the synaptic deficiencies that are associated with the early stages of the disease. Although the precise mechanisms that trigger synaptic dysfunction are still under investigation, the available data so far has enabled us to put forward a model that could be used as a guide to generate new therapeutic targets for pharmaceutical intervention.

@article{marsh2018-29722304,
  author  = {Marsh, J. and Alifragis, P.},
  title   = {{Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention}},
  journal = {Neural regeneration research},
  year    = {2018},
  doi     = {10.4103/1673-5374.230276},
  pmid    = {29722304},
  url     = {https://doi.org/10.4103/1673-5374.230276}
}

Key findings

• A significant contributing factor to the progression of the disease appears to be the progressive accumulation of amyloid-β42 (Aβ42), a small hydrophobic peptide.
• We discuss data that provide new insights on the Aβ42 induced pathology of Alzheimer's disease and a more detailed understanding of its contribution to the synaptic deficiencies that are associated with the early stages of the disease.

Study details

• Evidence strengthLow

Read the original

• DOI: 10.4103/1673-5374.230276
• PubMed: 29722304
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Related studies in Disease mechanisms

• Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments The Journal of biological chemistry · 2010-02-23 · usefulness score 36/100
• From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease Molecular neurobiology · 2012-07-26 · usefulness score 36/100
• The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease Alzheimer's research & therapy · 2016-10-03 · usefulness score 47/100
• Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers The Journal of physiology · 2006-02-09 · usefulness score 36/100
• Slow Wave Sleep Is a Promising Intervention Target for Alzheimer's Disease Frontiers in neuroscience · 2020-06-30 · usefulness score 41/100
• Small-Molecule Inhibitors of Amyloid Beta: Insights from Molecular Dynamics—Part A: Endogenous Compounds and Repurposed Drugs Pharmaceuticals · 2025-02-23 · usefulness score 37/100

Also tagged “precursor”

1,339 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.

• Activated Alzheimer disease platelets retain more beta amyloid precursor protein Neurobiology of aging · 1997-03-01 · usefulness score 41/100 · Risk genes beyond APOE
• Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study Nature communications · 2020-02-03 · usefulness score 61/100 · Prevention and risk
• Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease Alzheimer disease and associated disorders · 2006-04-01 · usefulness score 40/100 · Risk genes beyond APOE

Similar studies

• Mechanisms of synaptic dysfunction in Alzheimer's disease 1995 · Disease mechanisms
• Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease 2012 · Disease mechanisms
• Alzheimer's disease amyloid beta-protein and synaptic function 2010 · Disease mechanisms
• Alzheimer's disease: synaptic dysfunction and Abeta 2009 · Disease mechanisms
• Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors 2014 · Disease mechanisms
• The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease 2013 · Disease mechanisms

More on Disease mechanisms

• A review that covers this ground Amyloid beta: multiple mechanisms of toxicity and only some protective effects? Oxidative medicine and cellular longevity · 2014-02-05 · usefulness score 40/100
• Newest in this subject Aβ42 oligomers disrupt calcium homeostasis via Piezo1 and induce neurotoxicity in differentiated SH-SY5Y cells Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Neuronal Hyperactivity Induces Tau Phosphorylation Selectively in Excitatory Pyramidal Neurons Which Contributes to GluA2 Regulation bioRxiv · 2026-10-28 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Disease mechanisms →